Weighing Access and Affordability - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Weighing Access and Affordability
Policymakers must balance fundamental issues involving access to medicines and pricing.

Pharmaceutical Technology
Volume 36, Issue 11, pp. 30

The late Dr. Louis Lasagna, visionary father of the field of clinical pharmacology and founder of the Tufts University Center for the Study of Drug Development (CSDD), used to refer to the "cruel irony" of developing life-saving, breakthrough drugs that patients cannot afford. In many respects, this conundrum is playing itself out across many major pharmaceutical markets around the world.

Open markets, which allow for more flexible pricing strategies, offer a significant incentive to drug companies to seek approval in that region, thereby leading to a greater number of medicines reaching the marketplace despite the fact that some of these medicines may be unaffordable to some patients. At the other extreme, closed markets, which more closely regulate pharmaceutical prices and reimbursement, may lead to fewer new medicines reaching the marketplace. Those products, however, may be more affordably priced and, therefore, accessible to a greater number of patients.

The basic question for healthcare strategists and policymakers is the following: Do you want more drugs, knowing that some patients who need them may not be able to afford them, or do you want fewer drugs, which are affordable to all?

To explore this issue, Tufts CSDD conducted a study that looked at access to cancer drugs in the United States and the European Union and reviewed pricing and reimbursement restrictions in each region. The findings of the study, which was led by a co-author of this article, Joshua Cohen, were published in a recent issue of Tufts CSDD Impact Report (1).

Briefly, the study found that in the past decade, FDA approved more cancer drugs than its European counterpart, EMA, and for those drugs approved in both markets, FDA approved them more quickly. Moreover, third-party payers in the US, both private and public, approved a larger percentage of marketed drugs for reimbursement, but with a much higher patient-cost sharing than in Europe. In contrast, whereas fewer cancer drugs were approved in Europe, the prices of those drugs were, on average, 9% lower than in the US.

Although the study did not assess whether better access to the newest cancer drugs led to better health outcomes, the results highlight a key challenge for policy makers. Given that the annual tally of relatively expensive new cancer drugs is increasing, reimbursement will continue to be a significant concern in all healthcare systems. In this regard, policymakers may be well served by cautiously drawing lessons from the experiences, both positive and negative, of systems that have integrated economic evaluations into the prescribing and reimbursement decision-making process.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here